609 related articles for article (PubMed ID: 10428733)
1. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.
Yoshida H; Shiratori Y; Moriyama M; Arakawa Y; Ide T; Sata M; Inoue O; Yano M; Tanaka M; Fujiyama S; Nishiguchi S; Kuroki T; Imazeki F; Yokosuka O; Kinoyama S; Yamada G; Omata M
Ann Intern Med; 1999 Aug; 131(3):174-81. PubMed ID: 10428733
[TBL] [Abstract][Full Text] [Related]
2. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
[TBL] [Abstract][Full Text] [Related]
3. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403
[TBL] [Abstract][Full Text] [Related]
4. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival.
Shiratori Y; Ito Y; Yokosuka O; Imazeki F; Nakata R; Tanaka N; Arakawa Y; Hashimoto E; Hirota K; Yoshida H; Ohashi Y; Omata M;
Ann Intern Med; 2005 Jan; 142(2):105-14. PubMed ID: 15657158
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis.
Inoue A; Tsukuma H; Oshima A; Yabuuchi T; Nakao M; Matsunaga T; Kojima J; Tanaka S
J Epidemiol; 2000 Jul; 10(4):234-40. PubMed ID: 10959605
[TBL] [Abstract][Full Text] [Related]
6. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C.
Yoshida H; Tateishi R; Arakawa Y; Sata M; Fujiyama S; Nishiguchi S; Ishibashi H; Yamada G; Yokosuka O; Shiratori Y; Omata M
Gut; 2004 Mar; 53(3):425-30. PubMed ID: 14960528
[TBL] [Abstract][Full Text] [Related]
7. Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy.
Okanoue T; Minami M; Makiyama A; Sumida Y; Yasui K; Itoh Y
Clin Gastroenterol Hepatol; 2005 Oct; 3(10 Suppl 2):S89-91. PubMed ID: 16234069
[TBL] [Abstract][Full Text] [Related]
8. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy.
Shiratori Y; Imazeki F; Moriyama M; Yano M; Arakawa Y; Yokosuka O; Kuroki T; Nishiguchi S; Sata M; Yamada G; Fujiyama S; Yoshida H; Omata M
Ann Intern Med; 2000 Apr; 132(7):517-24. PubMed ID: 10744587
[TBL] [Abstract][Full Text] [Related]
9. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
[TBL] [Abstract][Full Text] [Related]
10. [Multicenter study on the inhibition of hepatocarcinogenesis by interferon therapy (IHIT)].
Yoshida H; Omata M
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):463-6. PubMed ID: 15359842
[No Abstract] [Full Text] [Related]
11. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.
Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T
J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762
[TBL] [Abstract][Full Text] [Related]
12. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group.
Okanoue T; Itoh Y; Minami M; Sakamoto S; Yasui K; Sakamoto M; Nishioji K; Murakami Y; Kashima K
J Hepatol; 1999 Apr; 30(4):653-9. PubMed ID: 10207807
[TBL] [Abstract][Full Text] [Related]
13. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.
Imai Y; Kawata S; Tamura S; Yabuuchi I; Noda S; Inada M; Maeda Y; Shirai Y; Fukuzaki T; Kaji I; Ishikawa H; Matsuda Y; Nishikawa M; Seki K; Matsuzawa Y
Ann Intern Med; 1998 Jul; 129(2):94-9. PubMed ID: 9669992
[TBL] [Abstract][Full Text] [Related]
14. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus.
Tateyama M; Yatsuhashi H; Taura N; Motoyoshi Y; Nagaoka S; Yanagi K; Abiru S; Yano K; Komori A; Migita K; Nakamura M; Nagahama H; Sasaki Y; Miyakawa Y; Ishibashi H
J Gastroenterol; 2011 Jan; 46(1):92-100. PubMed ID: 20711614
[TBL] [Abstract][Full Text] [Related]
15. Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon.
Veldt BJ; Hansen BE; Ikeda K; Verhey E; Suzuki H; Schalm SW
Scand J Gastroenterol; 2006 Sep; 41(9):1087-94. PubMed ID: 16938723
[TBL] [Abstract][Full Text] [Related]
16. [Hepatitis C: epidemiology and therapy--with special reference to long-term prognosis after IFN therapy].
Fujiyama S; Tanaka M
Rinsho Byori; 2000 Jan; 48(1):5-13. PubMed ID: 10756668
[TBL] [Abstract][Full Text] [Related]
17. Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis.
Cheinquer N; Cheinquer H; Wolff FH; Coelho-Borges S
Braz J Infect Dis; 2010; 14(5):457-61. PubMed ID: 21221473
[TBL] [Abstract][Full Text] [Related]
18. Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study.
Ikeda K; Saitoh S; Kobayashi M; Suzuki Y; Suzuki F; Tsubota A; Arase Y; Murashima N; Chayama K; Kumada H
J Gastroenterol Hepatol; 2001 Apr; 16(4):406-15. PubMed ID: 11354279
[TBL] [Abstract][Full Text] [Related]
19. Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis.
Masuzaki R; Yoshida H; Omata M
Oncology; 2010 Jul; 78 Suppl 1():17-23. PubMed ID: 20616579
[TBL] [Abstract][Full Text] [Related]
20. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
